Definium Therapeutics ($DFTX) Insider Trading & Smart Money Activity
Definium Therapeutics, Inc. ($DFTX) has 18 insider trades, 5 13F position changes and 7 analyst ratings on file. In the last 12 months on the open market, no insider bought and 10 insiders sold ($4.92M), net -$4.92M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 10
- Net insider $ (12 mo)
- -$4.92M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 5
- Analyst ratings on file
- 7
DFTX insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 5 · $2.62M | 0 / 0 | 3 / 2 |
| Q3 2026 | 0 | 5 · $2.30M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All DFTX insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Insider | Wiley Matthew T.Chief Commercial Officer | Sell (Open-market sale) 10b5-1 | 3.10K sh | $113.26K | +3.4% | — | |||||
| Insider | Sullivan MarkChief Legal Officer | Sell (Open-market sale) 10b5-1 | 14.05K sh | $513.85K | +3.4% | — | |||||
| Insider | Roberts BrandiChief Financial Officer | Sell (Open-market sale) 10b5-1 | 3.38K sh | $123.50K | +3.4% | — | |||||
| Insider | Karlin DanielChief Medical Officer | Sell (Open-market sale) 10b5-1 | 10.85K sh | $396.89K | +3.4% | — | |||||
| Insider | Barrow RobertChief Executive Officer | Sell (Open-market sale) 10b5-1 | 31.55K sh | $1.15M | +3.4% | — | |||||
| Analyst | Canaccord Genuity | Reiterates to buy | PT $58 | -5.4% | -5.4% | Read | |||||
| Insider | Matthew WileyChief Commercial Officer | Sell (Open-market sale) 10b5-1 | 2.87K sh | $129.10K | -1.3% | -4.8% | Read | ||||
| Insider | Mark SullivanChief Legal Officer | Sell (Open-market sale) 10b5-1 | 13.01K sh | $585.75K | -1.3% | -4.8% | Read | ||||
| Insider | Brandi RobertsChief Financial Officer | Sell (Open-market sale) 10b5-1 | 3.01K sh | $135.68K | -1.3% | -4.8% | Read | ||||
| Insider | Daniel KarlinChief Medical Officer | Sell (Open-market sale) 10b5-1 | 10.04K sh | $451.88K | -1.3% | -4.8% | Read | ||||
| Insider | Robert BarrowChief Executive Officer | Sell (Open-market sale) 10b5-1 | 29.21K sh | $1.32M | -1.3% | -4.8% | — | ||||
| Analyst | Jones Trading | Reiterates to buy | PT $74 | +3.0% | +2.5% | Read | |||||
| Analyst | Needham | Reiterates to buy | PT $50 | +30.0% | +18.7% | Read | |||||
| Analyst | Baird | Reiterates to buy | PT $57 | +30.0% | +18.7% | Read | |||||
| Analyst | Oppenheimer | Reiterates to buy | PT $60 | +26.9% | +19.1% | Read | |||||
| Analyst | Leerink Partners | Reiterates to buy | PT $52 | +26.9% | +19.1% | Read | |||||
| Insider | Matthew WileyChief Commercial Officer | Buy (Grant or award) | 62.50K sh | +26.9% | +19.1% | Read | |||||
| Insider | Mark SullivanChief Legal Officer | Buy (Grant or award) | 62.50K sh | +26.9% | +19.1% | Read | |||||
| Insider | Brandi RobertsChief Financial Officer | Buy (Grant or award) | 62.50K sh | +26.9% | +19.1% | Read | |||||
| Insider | Daniel KarlinChief Medical Officer | Buy (Grant or award) | 100K sh | +26.9% | +19.1% | Read | |||||
| Insider | Robert BarrowChief Executive Officer | Buy (Grant or award) | 375K sh | +26.9% | +19.1% | Read | |||||
| Analyst | Canaccord Genuity | Reiterates to buy | PT $38 | +49.8% | +82.5% | Read | |||||
| Insider | Andreas Krebs | Buy (Grant or award) | 19.19K sh | +1.5% | +81.0% | — | |||||
| Insider | Bruhn Suzanne Louise | Buy (Grant or award) | 4.67K sh | +1.5% | +81.0% | — | |||||
| Insider | Roger Adsett | Buy (Grant or award) | 3.56K sh | +1.5% | +81.0% | Read | |||||
| 13F | Rtw Investments | New | +300K sh | $14.11M | +7.2% | +13.2% | Read | ||||
| 13F | Driehaus Capital Management | Reduced | -625.31K sh | $146.32M | +7.2% | +13.2% | Read | ||||
| 13F | Driehaus Capital Management | Reduced | -625.31K sh | $278.10M | +7.2% | +13.2% | Read | ||||
| 13F | Avoro Capital Advisors | New | +5M sh | $123.75M | +7.2% | +13.2% | Read | ||||
| 13F | Avoro Capital Advisors | New | +5M sh | $235.20M | +7.2% | +13.2% | Read |
1W / 1M / 6M = how DFTX moved from the trade or filing date.
Insider trading in DFTX: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Wiley Matthew T. | Chief Commercial Officer | 1 | -$113.26K | Sep 25, 2026 | |
| Sullivan Mark | Chief Legal Officer | 1 | -$513.85K | Sep 25, 2026 | |
| Roberts Brandi | Chief Financial Officer | 1 | -$123.50K | Sep 25, 2026 | |
| Karlin Daniel | Chief Medical Officer | 1 | -$396.89K | Sep 25, 2026 | |
| Barrow Robert | Chief Executive Officer | 1 | -$1.15M | Sep 25, 2026 | |
| Matthew Wiley | Chief Commercial Officer | 2 | -$129.10K | Jun 25, 2026 | |
| Mark Sullivan | Chief Legal Officer | 2 | -$585.75K | Jun 25, 2026 | |
| Brandi Roberts | Chief Financial Officer | 2 | -$135.68K | Jun 25, 2026 | |
| Daniel Karlin | Chief Medical Officer | 2 | -$451.88K | Jun 25, 2026 | |
| Robert Barrow | Chief Executive Officer | 2 | -$1.32M | Jun 25, 2026 | |
| Andreas Krebs | 1 | — | Jun 11, 2026 | ||
| Bruhn Suzanne Louise | 1 | — | Jun 11, 2026 | ||
| Roger Adsett | 1 | — | Jun 11, 2026 |
Institutions moving DFTX (13F)
Analyst ratings on DFTX
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| Canaccord Genuity | Reiterates | buy | $58 | -5.4% | -5.4% | Read | ||
| Jones Trading | Reiterates | buy | $74 | +3.0% | +2.5% | Read | ||
| Needham | Reiterates | buy | $50 | +30.0% | +18.7% | Read | ||
| Baird | Reiterates | buy | $57 | +30.0% | +18.7% | Read | ||
| Oppenheimer | Reiterates | buy | $60 | +26.9% | +19.1% | Read | ||
| Leerink Partners | Reiterates | buy | $52 | +26.9% | +19.1% | Read | ||
| Canaccord Genuity | Reiterates | buy | $38 | +49.8% | +82.5% | Read |
Frequently asked questions
Are DFTX insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 10 insiders made 10 open-market sales worth $4.92M, a net -$4.92M.
What is the latest insider trade in DFTX?
Wiley Matthew T., Chief Commercial Officer filed a sell (open-market sale) of 3.10K sh worth $113.26K on Sep 25, 2026.
Which institutions changed their DFTX positions?
Recent 13F filers moving the stock include Driehaus Capital Management, Avoro Capital Advisors and Rtw Investments.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.